Evolving strategies for the use of combination therapy in hypertension

被引:32
作者
Gradman, AH [1 ]
Acevedo, C [1 ]
机构
[1] Temple Univ, Western Penn Hosp, Sch Med, Pittsburgh, PA 15224 USA
关键词
D O I
10.1007/s11906-002-0062-x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Two thirds of patients with hypertension require more than one drug to achieve goal blood pressure. Rational antihypertensive drug combinations are based on their ability to produce additive blood pressure reduction and reduce the incidence of dose-dependent side effects. Some combinations exhibit side-effect neutralization in which side effects associated with one drug are neutralized by a second agent. Fixed-dose combinations improve adherence by reducing the number of pills and simplifying the treatment regimen. Because volume overload is common, low-dose diuretics are often included in drug combinations. Combinations of diuretics with potassium-sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers are useful in treating large segments of the hypertensive population. Combinations of calcium channel blockers and angiotensin converting enzyme inhibitors are also effective and reduce the incidence of calcium blocker-related edema. Combinations of agents affecting the renin-angiotensin system by different mechanisms are currently the subject of active investigation.
引用
收藏
页码:343 / 349
页数:7
相关论文
共 19 条
  • [1] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
    Agodoa, LY
    Appel, L
    Bakris, GL
    Beck, G
    Bourgoignie, J
    Briggs, JP
    Charleston, J
    Cheek, D
    Cleveland, W
    Douglas, JG
    Douglas, M
    Dowie, D
    Faulkner, M
    Gabriel, A
    Gassman, J
    Greene, T
    Hall, Y
    Hebert, L
    Hiremath, L
    Jamerson, K
    Johnson, CJ
    Kopple, J
    Kusek, J
    Lash, J
    Lea, J
    Lewis, JB
    Lipkowitz, M
    Massry, S
    Middleton, J
    Miller, ER
    Norris, K
    O'Connor, D
    Ojo, A
    Phillips, RA
    Pogue, V
    Rahman, M
    Randall, OS
    Rostand, S
    Schulman, G
    Smith, W
    Thornley-Brown, D
    Tisher, CC
    Toto, RD
    Wright, JT
    Xu, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2719 - 2728
  • [2] Bakris George L., 1999, J Clin Hypertens (Greenwich), V1, P141
  • [3] Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy
    Bakris, GL
    Weir, MR
    DeQuattro, V
    McMahon, FG
    [J]. KIDNEY INTERNATIONAL, 1998, 54 (04) : 1283 - 1289
  • [4] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [5] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [6] Eplerenone reduces proteinuria in type II diabetes mellitus: Implications for aldosterone involvement in the pathogenesis of renal dysfunction
    Epstein, M
    Buckalew, V
    Altamirano, J
    Roniker, B
    Krause, S
    Kleiman, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 249A - 249A
  • [7] Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension
    Flack, JM
    Saunders, E
    Gradman, A
    Kraus, WE
    Lester, FM
    Pratt, JH
    Alderman, M
    Green, S
    Vargas, R
    Espenshade, M
    Ceesay, P
    Alexander, J
    Goldberg, A
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (08) : 1193 - 1208
  • [8] A MULTIFACTORIAL TRIAL DESIGN TO ASSESS COMBINATION THERAPY IN HYPERTENSION - TREATMENT WITH BISOPROLOL AND HYDROCHLOROTHIAZIDE
    FRISHMAN, WH
    BRYZINSKI, BS
    COULSON, LR
    DEQUATTRO, VL
    VLACHAKIS, ND
    MROCZEK, WJ
    DUKART, G
    GOLDBERG, JD
    ALEMAYEHU, D
    KOURY, K
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (13) : 1461 - 1468
  • [9] Combined enalapril and felodipine extended release (ER) for systemic hypertension
    Gradman, AH
    Cutler, NR
    Davis, PJ
    Robbins, JA
    Weiss, RJ
    Wood, BC
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (04) : 431 - 435
  • [10] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762